Factors influencing success in endoscopic treatment of grade 4-5 primary Vesicoureteric Reflux (VUR) in infancy and childhood
Factors influencing success in endoscopic treatment of grade 4-5 primary Vesicoureteric Reflux (VUR) in infancy and childhood
Introduction: there is equipoise among pediatric urologists regarding endoscopic versus surgical intervention for symptomatic Grade 4-5 Vesicoureteric Reflux (VUR), particularly in infancy. Our aim was to assess outcomes of first-line endoscopic treatment in all cases of symptomatic Grade 4-5 VUR and we hypothesised that using endoscopic Dx/HA as first line management for primary VUR would obviate the need for ureteric reimplantation in the majority of cases.
Methods: retrospective single-surgeon analysis of consecutive patients with primary Grade 4-5 VUR over 15 years. Indication for intervention was breakthrough UTI on prophylaxis. Endoscopic dextranomer/hyaluronic acid co-polymer (Dx/HA; Deflux®) injection was first-line procedure. Primary outcomes were both post-procedure febrile culture positive urinary tract infection (UTI) and VUR recurrence on post-operative VCUG requiring further surgical intervention. We postulated that risk factors influencing outcome are: age under 1 year, female gender, postnatal versus antenatal presentation, duplex anatomy, circumcision status and presence of congenital uptake defects on DMSA. Data analysed using Fisher's Exact Test/Multivariate Analysis.
Results: 77 patients with Grade 4-5 VUR were identified, of whom 49 (11 bilateral) underwent a Dx/HA injection at median 12 (3-84) months. Median follow-up post-injection was 32 (2–145) months. There were no reported complications or ureteral obstruction. Sixteen (33 %) patients suffered a febrile UTI at follow-up; on further investigation, half (8/16) of these were found to have recurrent VUR. Therefore 67 % were symptom free and 84 % did not require further intervention after one injection (41/49), and 98 % after further injections (48/49). Duplex systems had a similar outcome of 80 % not requiring further intervention. On multivariate analysis, males were found to have a significantly better outcome than females (p < 0.015) irrespective of circumcision status. Forty-one percent of the children in our cohort had uptake defects on DMSA prior to intervention, but this did not have any difference on outcome. Conclusion: Endoscopic Dx/HA injection is a safe first-line, day-case treatment for Grade 4-5 VUR in children of any age, with a low complication rate. Two-thirds of patients are asymptomatic after one injection; 84 % do not require further procedures after one injection, and 98 % after 2 injections.
Deflux injection, Dextranomer hyaluronic acid, Endoscopic injection, Endoscopic treatment, Hydrodistension, Renal scarring, Subureteric injection, Urinary tract infection, VUR children, Vesicoureteral reflux, Vesicoureteric reflux
Tiboni, Sonia G.
de3663a4-0685-4bba-9cff-5b63f8c9e362
Bethell, George S.
c7a62cc1-5573-41f6-ae00-3c11e8219dd4
Davidson, Joseph R.
b3ad4bdf-41e0-4af1-a2b5-2c65cd72b6ae
Farrugia, Marie-Klaire
97b4bf3c-23d4-4640-8a48-970f4c99ebfd
March 2025
Tiboni, Sonia G.
de3663a4-0685-4bba-9cff-5b63f8c9e362
Bethell, George S.
c7a62cc1-5573-41f6-ae00-3c11e8219dd4
Davidson, Joseph R.
b3ad4bdf-41e0-4af1-a2b5-2c65cd72b6ae
Farrugia, Marie-Klaire
97b4bf3c-23d4-4640-8a48-970f4c99ebfd
Tiboni, Sonia G., Bethell, George S., Davidson, Joseph R. and Farrugia, Marie-Klaire
(2025)
Factors influencing success in endoscopic treatment of grade 4-5 primary Vesicoureteric Reflux (VUR) in infancy and childhood.
Journal of Pediatric Surgery, 60 (3), [162157].
(doi:10.1016/j.jpedsurg.2025.162157).
Abstract
Introduction: there is equipoise among pediatric urologists regarding endoscopic versus surgical intervention for symptomatic Grade 4-5 Vesicoureteric Reflux (VUR), particularly in infancy. Our aim was to assess outcomes of first-line endoscopic treatment in all cases of symptomatic Grade 4-5 VUR and we hypothesised that using endoscopic Dx/HA as first line management for primary VUR would obviate the need for ureteric reimplantation in the majority of cases.
Methods: retrospective single-surgeon analysis of consecutive patients with primary Grade 4-5 VUR over 15 years. Indication for intervention was breakthrough UTI on prophylaxis. Endoscopic dextranomer/hyaluronic acid co-polymer (Dx/HA; Deflux®) injection was first-line procedure. Primary outcomes were both post-procedure febrile culture positive urinary tract infection (UTI) and VUR recurrence on post-operative VCUG requiring further surgical intervention. We postulated that risk factors influencing outcome are: age under 1 year, female gender, postnatal versus antenatal presentation, duplex anatomy, circumcision status and presence of congenital uptake defects on DMSA. Data analysed using Fisher's Exact Test/Multivariate Analysis.
Results: 77 patients with Grade 4-5 VUR were identified, of whom 49 (11 bilateral) underwent a Dx/HA injection at median 12 (3-84) months. Median follow-up post-injection was 32 (2–145) months. There were no reported complications or ureteral obstruction. Sixteen (33 %) patients suffered a febrile UTI at follow-up; on further investigation, half (8/16) of these were found to have recurrent VUR. Therefore 67 % were symptom free and 84 % did not require further intervention after one injection (41/49), and 98 % after further injections (48/49). Duplex systems had a similar outcome of 80 % not requiring further intervention. On multivariate analysis, males were found to have a significantly better outcome than females (p < 0.015) irrespective of circumcision status. Forty-one percent of the children in our cohort had uptake defects on DMSA prior to intervention, but this did not have any difference on outcome. Conclusion: Endoscopic Dx/HA injection is a safe first-line, day-case treatment for Grade 4-5 VUR in children of any age, with a low complication rate. Two-thirds of patients are asymptomatic after one injection; 84 % do not require further procedures after one injection, and 98 % after 2 injections.
Text
VUR Final accepted version
- Accepted Manuscript
Restricted to Repository staff only until 6 January 2026.
Request a copy
More information
Accepted/In Press date: 1 January 2025
e-pub ahead of print date: 6 January 2025
Published date: March 2025
Keywords:
Deflux injection, Dextranomer hyaluronic acid, Endoscopic injection, Endoscopic treatment, Hydrodistension, Renal scarring, Subureteric injection, Urinary tract infection, VUR children, Vesicoureteral reflux, Vesicoureteric reflux
Identifiers
Local EPrints ID: 501068
URI: http://eprints.soton.ac.uk/id/eprint/501068
ISSN: 0022-3468
PURE UUID: 593b6820-90b7-445a-8978-4b347b0e2a02
Catalogue record
Date deposited: 22 May 2025 16:37
Last modified: 23 May 2025 02:06
Export record
Altmetrics
Contributors
Author:
Sonia G. Tiboni
Author:
George S. Bethell
Author:
Joseph R. Davidson
Author:
Marie-Klaire Farrugia
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics